Importantly, EGFR inhibition with the monoclonal antibody cetuximab (C225) in combination with radiotherapy has been shown to increase locoregional control and survival in HNSCC patients (4). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.